Zimmer Biomet (NYSE:ZBH) Shares Break Below Fifty Day Moving Average – What’s Next?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH)’s share price crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $94.86 and traded as low as $94.38. Zimmer Biomet shares last traded at $94.54, with a volume of 3,605,958 shares traded.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZBH. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research report on Thursday, August 6th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Argus restated a “buy” rating and issued a $125.00 price target on shares of Zimmer Biomet in a research note on Thursday, October 22nd. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Stock Down 3.0%

The firm has a market cap of $18.03 billion, a price-to-earnings ratio of 23.00, a price-to-earnings-growth ratio of 2.34 and a beta of 0.49. The stock’s 50 day moving average is $94.86 and its 200 day moving average is $91.70. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s payout ratio is currently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Zimmer Biomet during the second quarter valued at approximately $1,344,282,000. State Street Corp boosted its holdings in Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new position in Zimmer Biomet in the second quarter worth approximately $328,578,000. Dimensional Fund Advisors LP grew its position in Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after buying an additional 24,208 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Zimmer Biomet in the second quarter worth approximately $187,480,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.